RAMM Pharma Corp. Announces Corporate Update

Published: March 29, 2024

RAMM Pharma Corp. Announces Corporate Update

RAMM Pharma Corp. advised its shareholders that in accordance with its previously announced strategy of diversifying its product portfolio, in order to reduce its exposure to the strictly regulated environment of Cannabis-based products, it has launched the formulation and production of a full line of botanical-derived food supplements, through its subsidiary Hempoland Sp Zoo (“Hempoland”) under its Marishanti brand.

The Company expresses its recognition and thanks to the R&D, Quality and Production teams of Hempoland for their commitment and ongoing professional excellence. Hempoland has successfully filed notification to the Competent Regulatory Authority for the first phase of its health supportive portfolio and has commenced sales in the EU with a view to international expansion including its online presence.

The product line available by April 30th, 2024, includes and will include:

 – Hypericum Perforatum (“St. John’s Wort”)
 – Valeriana Officinalis L. (“Valerian Root”)
–  Calendula Officinalis L. (“Marigold Flower”)
–  Salvia Officinalis L. (“Sage Leaf”)
–  Taraxacum Officinale F.H. Wigg (“Dandelion Root”)
–  Crataegus spp (“Hawthorn”)
–  Melissa Officinalis L. (“Melissa Leaf”)
–  Ribes Nigrum L. (“Blackcurrant”)

The beneficial properties of the above have been extensively tested and documented in numerous academic reviews and research papers. Additional SKUs, including non-restrictive functional mushroom, are under current development and Management expects to commence sales in 3Q2024.

The use of plant extracts is experiencing strong growth in the global market as consumers seek out natural and healthy products with beneficial properties. The urban population, with evolving lifestyles, has become increasingly health-conscious resulting in wider acceptance of alternative natural products fuelling the growth of botanical-derived food supplements. The global plant-extract market was estimated at USD 34.4 billion in 2022 and it is projected to grow at a CAGR of 12.3% to reach USD 61.5 billion by 2027 (source: www.marketsandmarkets.com).

About RAMM Pharma Corp.
RAMM Pharma is a leader in the field of cannabinoid pharmacology and product formulation for cannabis- based pharmaceuticals and other hemp-based products with a unique and diversified international production and sales platform. The Company operates an established pharmaceutical and medical product business in Uruguay that has developed several medically registered and approved plant -derived cannabinoid pharmaceutical products that have been authorized for sale and/or compassionate use in several Latin American countries. RAMM also has a pipeline of new products, including registered hemp- based nutrition and specialized veterinary products, in various stages of approval and development, which are produced at the company’s state-of-the-art, good-manufacturing-practice-certified formulation facility in Montevideo, Uruguay and Elblag, Poland. Additional information about the Company is available at www.wearerammpharma.com.